immatics has a solid financial basis, with leading international life science investors supporting its business.
Through its series A financing round in 2004/2005, immatics raised more than € 14 million from top tier venture capital firms.
In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional € 40 million to support the success story of immatics.
A series C financing round of €54 million was raised in September 2010 with approximately half of the investment coming from new investors MIG AG and AT Impf GmbH.
AT Impf GmbH
Dievini Hopp BioTech Holding GmbH & Co.KG
-/ www.dievini.com
EMBL Ventures
-/ www.embl-ventures.com
Grazia Equity
-/ www.grazia-equity.com
KfW Anstalt des öffentlichen Rechts
-/ www.kfw.de
L-EA
-/ www.l-ea.de
MIG AG
-/ www.mig.ag
Merifin Capital
-/ www.merifin.com
National Technology Enterprises Company
-/ www.ntec.com.kw
Vinci Capital/Renaissance
-/ www.vincicapital.ch
-/ www.renaissance-pme.ch
Wellington Partners
-/ www.wellington-partners.com

















































